181 related articles for article (PubMed ID: 17564935)
1. The therapeutic effects of intravitreal bevacizumab in a patient with recalcitrant idiopathic polypoidal choroidal vasculopathy.
Ghajarnia M; Kurup S; Eller A
Semin Ophthalmol; 2007; 22(2):127-31. PubMed ID: 17564935
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy.
Lai TY; Chan WM; Liu DT; Luk FO; Lam DS
Br J Ophthalmol; 2008 May; 92(5):661-6. PubMed ID: 18356265
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.
Wakabayashi T; Gomi F; Sawa M; Tsujikawa M; Nishida K
Br J Ophthalmol; 2012 Mar; 96(3):394-9. PubMed ID: 21719568
[TBL] [Abstract][Full Text] [Related]
4. Sequential therapy with intravitreal bevacizumab and photodynamic therapy for idiopathic polypoidal choroidal vasculopathy.
Pai SA; Shetty R
Acta Ophthalmol; 2009 Nov; 87(7):806-7. PubMed ID: 18721250
[No Abstract] [Full Text] [Related]
5. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.
Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S
Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
Ladas ID; Kotsolis AI; Papakostas TD; Rouvas AA; Karagiannis DA; Vergados I
Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
8. Three-year visual outcome of photodynamic therapy plus intravitreal bevacizumab with or without subtenon triamcinolone acetonide injections for polypoidal choroidal vasculopathy.
Sakai T; Ohkuma Y; Kohno H; Hayashi T; Watanabe A; Tsuneoka H
Br J Ophthalmol; 2014 Dec; 98(12):1642-8. PubMed ID: 25053762
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration.
Smith BT; Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA
Retina; 2008 May; 28(5):675-81. PubMed ID: 18463509
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
11. Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization.
Inoue M; Kadonosono K; Watanabe Y; Sato S; Kobayashi S; Yamane S; Ito R; Arakawa A
Retina; 2010 May; 30(5):733-8. PubMed ID: 20168271
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration.
Chen E; Kaiser RS; Vander JF
Retina; 2007; 27(4):445-50. PubMed ID: 17420696
[TBL] [Abstract][Full Text] [Related]
13. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome.
Kang HM; Koh HJ; Lee CS; Lee SC
Am J Ophthalmol; 2014 Mar; 157(3):598-606.e1. PubMed ID: 24269378
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Gomi F; Sawa M; Sakaguchi H; Tsujikawa M; Oshima Y; Kamei M; Tano Y
Br J Ophthalmol; 2008 Jan; 92(1):70-3. PubMed ID: 17567661
[TBL] [Abstract][Full Text] [Related]
15. Treatment of choroidal neovascularization using intravitreal bevacizumab.
Pedersen R; Soliman W; Lund-Andersen H; Larsen M
Acta Ophthalmol Scand; 2007 Aug; 85(5):526-33. PubMed ID: 17511757
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome.
Ehrlich R; Ciulla TA; Maturi R; Kheradiya NS; Hrisomalos N; Shulman S; Guess MG; Coyle E; Harris A
Retina; 2009; 29(10):1418-23. PubMed ID: 19898179
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization.
Mandal S; Garg S; Venkatesh P; Mithal C; Vohra R; Mehrotra A
Arch Ophthalmol; 2007 Nov; 125(11):1487-92. PubMed ID: 17998509
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.
Bom Aggio F; Eid Farah M; Melo GB
Acta Ophthalmol Scand; 2006 Oct; 84(5):713-4. PubMed ID: 16965511
[No Abstract] [Full Text] [Related]
19. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.
Gomi F; Sawa M; Wakabayashi T; Sasamoto Y; Suzuki M; Tsujikawa M
Am J Ophthalmol; 2010 Jul; 150(1):48-54.e1. PubMed ID: 20609707
[TBL] [Abstract][Full Text] [Related]
20. HALF-DOSE PHOTODYNAMIC THERAPY COMBINED WITH BEVACIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
Lee JH; Lee WK
Retina; 2015 Aug; 35(8):1561-8. PubMed ID: 25768248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
